Phase II Study of Carboplatin Combined with Biweekly Docetaxel for Advanced Non-small Cell Lung Cancer
Osamu Ishimoto(Sendai Kousei Hospital), Toshihiro Nukiwa(Tohoku University), Takashi Ishida(Keio University), Yukihiro Hasegawa(Tokyo Metropolitan Children's Medical Center), Sadahiro Koinumaru, Yasuo Saijo(Ho Chi Minh City International University), Shunichi Sugawara(Sendai Kousei Hospital), Toshiro Suzuki(Sendai Kousei Hospital), Hiroshi Miki(Takeda (Japan)), Mitsuru Munakata(Fukushima Medical University), Akira Inoue(Tohoku University Hospital)
Cited by 6
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953